HomeNDC LookupDrug shortages › Ivabradine Solution

Ivabradine Solution shortage

Ivabradine Solution is currently listed in shortage by the FDA. The FDA lists 1 affected product. This page was last refreshed from FDA data on Sep 22, 2026.

To Be Discontinued ⚠ Supply risk: High Cardiovascular 1 product 182 days First posted Mar 24, 2026 Updated Mar 24, 2026
Here’s the bottom line

Amgen is permanently stopping production of ivabradine oral solution (5 mg/5 mL). No other manufacturer of this form is currently listed as having supply available.

Don’t stop or change your therapy on your own — talk with your prescriber about the plan that fits you, and ask your pharmacist what’s actually available (see options).

Do you take this drug? See the ‘What to do’ recommendation from Dr. Brian Staiger, PharmD →
1
Affected NDCs
1
Reporting manufacturers
0/1
Reporting mfrs supplying
0/1
Affected strengths supplied
182
Days in shortage
164
Medicaid Rx (2026)
Source: FDA Drug Shortages Database API (openFDA). Last refreshed Sep 22, 2026 · today

What’s in shortage — at a glance

These figures count only the manufacturers that reported this shortage to the FDA — not every company that makes Ivabradine Solution. Other makers that haven’t reported a problem are shown in the green card below.

Availability of affected NDCs
From the FDA shortage report
1 NDCs
To be discontinued 1
Affected strengths still supplied
Among manufacturers reporting this shortage
0/1 strengths
No supply 1
FDA-reporting manufacturers with supply
Among manufacturers reporting this shortage
0/1 makers
No supply 1
✓ Other manufacturers not reporting a shortage
Still-marketed Ivabradine Solution from companies that have not filed an FDA shortage — these are not counted in the figures above. Stock can still vary by pharmacy.
Plus 8 alternative dosage forms of Ivabradine.
See all other options & details →
Shortage timeline
  1. Mar 24, 2026
    Currently in shortage
    1 of 1 product affected.
  2. Mar 24, 2026
    First reported to the FDA
    1 product first listed.

Built from FDA posting and update dates. The end date FDA publishes is the posting/update date, not a true resolution date, so durations are approximate.

What exactly is on backorder — by manufacturer

Manufacturer: Amgen Inc. 📞 1-800-772-6436 1 NDC click to expand
Status NDC / product Strength Availability Related information Reason
To Be Discontinued Corlanor, Solution, 5 mg/5 mL (NDC 55513-813-28) NDC 55513-0813-28 Discontinuation of the manufacture of the drug product

These rows are manufacturer reports to the FDA for Ivabradine Solution — they do not necessarily cover every manufacturer that makes this drug. A company appears here only if it told the FDA it has a supply problem, so other makers may still have stock. That’s the basis for the Where else can I get Ivabradine Solution? options further down this page.

Why is Ivabradine Solution in shortage?

Amgen has reported to the FDA that they are permanently stopping production of Corlanor oral solution, which is the liquid form of ivabradine at a strength of 5 mg/5 mL. This specific package (NDC 55513-813-28) will no longer be manufactured by them going forward.

Amgen did not share a more specific public reason for why they made this decision — just that they are discontinuing the manufacture of this particular product. It's also worth noting that this report reflects only what Amgen has filed with the FDA, so it speaks only to their version of this liquid formulation, not necessarily to every form or maker of ivabradine out there.

Based on the manufacturer-reported reason(s) and notes on file with the FDA for Ivabradine Solution, summarized in plain English by HelloPharmacist. A drug can be short for more than one reason, and the FDA updates these as manufacturers report changes.

What should I do if I take Ivabradine Solution?

Ivabradine oral solution (5 mg/5 mL) is currently on the FDA drug-shortage list, and the manufacturer that filed this report has listed it as being discontinued.

The one strength covered here — 5 mg/5 mL — has no available source reported right now. The reason given is a discontinuation of the manufacture of the drug product, filed by Amgen (for Corlanor solution). Because this is a discontinuation rather than a short-term delay, this supply problem may be permanent, so a conversation with your prescriber is the right next step. No other maker of this oral solution is listed in our records, though this report reflects only the manufacturer who filed it.

What you can do:

  1. Do not stop, skip, or change your dose on your own — keep taking your medicine as prescribed while you sort this out.
  2. Ask your pharmacy to check with wholesalers and other suppliers, since local stock can differ from national reports.
  3. Because this strength is listed as discontinued, ask your prescriber or pharmacist about options — for example a clinician-chosen alternative that fits your needs.

The manufacturer contact number is listed on this page for reference; pharmacies usually handle those calls. This is general information from national data and is not individualized medical advice.

See “Where else can I get Ivabradine Solution?” below ↓ The same medicine from manufacturers not reporting a shortage, alternative dosage forms, and therapeutic equivalents with pricing.
If you are a patient:
  • Don’t stop or change the medication on your own — talk to your prescriber first.
  • If this is part of an ongoing or essential regimen (for example HIV treatment or prevention, seizure, heart, transplant, diabetes or mental-health medicines), do not skip or ration doses — contact your pharmacist or prescriber right away to arrange continued supply before you run out.
  • Ask your pharmacy to check other manufacturers, strengths, package sizes, and nearby stores.
  • Ask your prescriber whether a different strength, formulation, or the brand/generic version is appropriate.
Keep reading
Our full Ivabradine guide

Uses, dosing, side effects, prices, and the complete FDA label — written in plain English and pharmacist-reviewed.

Read the Ivabradine guide →

Where else can I get Ivabradine Solution?

FDA shortages are manufacturer-reported — a company only shows up on the shortage list if it told the FDA it has a supply problem, so not every maker of Ivabradine Solution is necessarily short. Below we pull together the other still-marketed options that are not reported in shortage: the same medicine from manufacturers that haven’t reported a problem, and alternative dosage forms. These may still be out of stock at your pharmacy, and only your prescriber or pharmacist can decide what’s right for you.

Alternative dosage forms of Ivabradine

A different form of the same drug (for example a solution when capsules are short). A form change is a clinical decision — ask your prescriber:

Therapeutic equivalents & pricing 1 productclick to expand

Orange Book–rated equivalents of the affected strengths, with the latest NADAC price (a federal retail-acquisition benchmark, not your copay) and an evidence-based availability label. Cheapest first.

ProductManufacturerPackageNADAC $/unitAB ratingAvailability
Corlanor 5 mg/5mLNDC 55513-0813-28 Amgen 28 ampules FDA listed

Equivalents share the same ingredient, strength, dosage form and route; an AB rating means the FDA considers them substitutable. NADAC is a national retail-pharmacy acquisition benchmark from CMS — not what you pay. Availability is inferred from recent pricing, not a stock check.

Identity & classification

GCN Seq No 079666
GCN 46204
HICL code 033396
Ingredient (HICL) Ivabradine Hcl
HIC1 code A
Therapeutic class — broad (HIC1) Cardiovascular System
HIC2 code A2
Therapeutic class — intermediate (HIC2) Cardiac Depressants
HIC3 code A2B
Therapeutic class — specific (HIC3) Heart Rate Reducing,Sa Selective I(F) Current Inh.
AHFS code 24:04.08.00
AHFS class Cardiotonic Agents
FDB label name CORLANOR 5 MG/5 ML ORAL SOLN
FDB brand name Corlanor
Legend status F — Federal legend — prescription drug or device
GPI-1440700035102020
GPI classCorlanor
Where does this data come from?
Identity codes come from First Databank (FDB) (HICL ingredient, HIC1–3 therapeutic-class hierarchy, GCN, AHFS class, legend status) and Medi-Span GPI, mapped from a representative affected NDC. Licensed reference data — for identification only.

Other cardiovascular shortages

Ivabradine Solution shortage FAQs

Is Ivabradine Solution in shortage?
Yes — the FDA currently lists Ivabradine Solution in shortage (status: “To Be Discontinued”, first reported Mar 24, 2026). 1 of 1 product is affected. This is national, manufacturer-reported data, so your pharmacy may still have stock.
Which products are affected?
Corlanor, Solution, 5 mg/5 mL (NDC 55513-813-28) (NDC 55513-0813-28). The full per-NDC list (availability, manufacturer and status) is in the table above — each NDC links to its own page.
When will Ivabradine Solution be available again?
The FDA does not publish a guaranteed restock date, and no estimated-recovery note is on file. Availability can change daily — confirm with your pharmacy.
Can I still get Ivabradine somewhere?
8 alternative dosage forms of Ivabradine are also listed. See “Where else can I get Ivabradine Solution?” above — stock still varies by pharmacy.
What should I do if I take Ivabradine Solution?
Don’t stop or change it on your own. Ask your pharmacist whether they can order it from another manufacturer or a different strength/package size, and ask your prescriber about a long-term plan before your supply runs out.

Still have a question about the Ivabradine Solution shortage?

Ask a pharmacist about this shortage →
How to read the Supply-Risk rating
Low (1–2)Multiple manufacturers still supplying and most strengths or pack sizes sourceable.
Medium (3)Some constraint — fewer suppliers or a notable share of NDCs unavailable.
High (4–5)Down to a single source, most strengths or pack sizes unsourceable, or a long-running outage.
Where does this data come from?
Shortage records come from the FDA Drug Shortages Database API via openFDA (/drug/shortages) — drug, manufacturer & contact, NDC/product, status, availability, reason, therapeutic category and posting/update dates. Current / To Be Discontinued = active; Resolved is kept for history. The Supply-Risk rating is assessed per active ingredient and adds the FDA NDC Directory (still-marketed manufacturers by ingredient & form); same-medicine and equivalent products use First Databank classification + CMS NADAC pricing; Medicaid use + most-affected states come from CMS Medicaid State Drug Utilization Data. Reference only — confirm current status with the manufacturer or FDA before acting on it.
Data structure & sourcing designed and verified by Dr. Brian Staiger, PharmD.
← Back to all current drug shortages